Dr Sally Shrapnel became one of Australia's leading scientists in her area after taking a quantum leap
Based at the University of Queensland, she's since become one of Australia's leading quantum scientists.
Before transitioning to science full-time, Dr Shrapnel split her week between working as a doctor and writing her PhD on exploring the mysteries behind quantum theory.
The associate professor's interest in the fundamental laws of the universe began at a young age.
Dr Shrapnel grew up in a house full of science fiction books and would devour each one at a rapid pace.
Her favourite book from her childhood was John Wyndham's 1960 Trouble with Lichen, which centred around a young female biochemist.
"I was about eight or nine [years old] when I read that, but just this idea of a female scientist was pretty cool," Dr Shrapnel said.
Her curiosity about how the world worked and a desire to find scientific explanations continued into adulthood.
Dr Shrapnel had planned to be a radiologist, but while studying for her radiology exam, she fell in love with working as a GP in the small regional town of Bothwell in Tasmania.
"It was the first time I got to ... really put into practice all the stuff I'd learnt," she said.
Her career as a general practitioner led to her working across Tasmania, Queensland, and the United Kingdom.
But while she enjoyed the social side of working as a doctor, she was missing the "techie" aspects of science.
Dr Shrapnel, who now hopes to inspire the next generation of female scientists, decided she had "a bit more space in her brain" to take on further study once her "two beautiful boys" started primary school.
While working as a GP, Dr Shrapnel said she had to explain complex scientific ideas in simple terms for her patients to understand.
"I was really kind of fascinated by the nature of scientific explanation," she said.
"It led me to kind of be wondering, 'What is it about the world that makes scientific explanation true? Why do we believe in science?'
Dr Shrapnel returned to university in her early 40s, when she enrolled into a diploma in philosophy at the University of Queensland.
During her studies, she learnt there were well-developed philosophical theories around why we believe scientific explanations are true, but "all of them had this little footnote that says, 'except for quantum theory'".
To her, that seemed to be saying "quantum theory we can't [or] we don't understand … let's just ignore that bit", she said.
"I was like, 'Wow, this is some part of science that we use [in practice] ... we're building quantum computers, and yet there's all these mysteries around why it's true'."
A fascination with wanting to understand those mysteries led her to complete a PhD in quantum theory.
"[It's] our most fundamental theory ... [the] physical theory of how the world works," she said.
While studying, Dr Shrapnel continued to split her time, spending three days as a GP and then two days working on her PhD, exploring the quantum world.
Now working full-time as a physicist, her research explores how quantum principles can inform and potentially improve artificial intelligence (AI) and machine learning.
She is developing new algorithms and theoretical frameworks that could one day inform and potentially improve AI, including in areas such as healthcare decision-making.
This year marks 100 years since the quantum revolution began and some say it's a theory that's as important to the understanding of the world as Charles Darwin's theory of evolution was.
The United Nations (UN) marked the occasion by declaring 2025 to be the International Year of Quantum Science and Technology.
Quantum technology is used in smart phones, medical imaging, manufacturing and elsewhere.
Until recently, Dr Shrapnel was the deputy director of the Australian Research Council (ARC) Centre of Excellence for Engineered Quantum Systems (EQUS), which officially ended in May.
Dr Shrapnel described Australia as the "quiet achiever" in the field.
During its time, scientists at EQUS developed the world's first focused research program on systems engineering in the quantum regime, according to its website.
It connected and supported academics from UQ, the University of Sydney, Macquarie University, the Australian National University and the University of Western Australia.
This year marked the end of EQUS's maximum 14-year funding term, but Dr Shrapnel said its legacy will live on through its alumni, including a group of impressive female scientists.
The centre has resulted in 10 startups and its alumni have gone on to lead quantum ventures across Australia and internationally.
That includes stand-out Iceberg Quantum, which has secured $2 million in pre-seed funding, and is partnering with global quantum computing leader PsiQuantum.
"Redback Systems, another EQUS spin-out, created a compact, highly accurate light sensor called a spectrometer, now used by scientists and companies around the world," Dr Shrapnel said.
Dr Shrapnel and her fellow researchers describe EQUS's closure as "the end of the beginning".
And she said its legacy goes beyond the science.
"If there's anything that came out of EQUS that I'm most proud of, it's we've got this cohort of incredible women who [are] really well set up to lead Australia into the next quantum revolution," Dr Shrapnel said.
"There were very few females in physics back in 2011. But our initiatives have drawn these incredible, talented women from all around the world."
Dr Shrapnel said she is now living the life she had read about as a child.
"It's like you get to be a sci-fi novelist and then try to provide the mathematical justification for your seemingly crazy ideas," she said.
Her advice to young aspiring female scientists is not to be intimidated by quantum science.
In fact, she characterised it as the "most exciting and interesting area of science that you can work in".
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
43 minutes ago
- News.com.au
ASX biotechs join global race for cell therapy breakthroughs
ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to 'break new ground' in treatment of solid tumours with CAR-T and NK cell assets Cell therapies represent a promising frontier in modern medicine, offering potential to treat, and in some cases cure diseases previously considered untreatable. By using living cells, either from the patient (autologous) or a donor (allogeneic), cell therapies aim to repair, replace, or enhance biological functions within the body. Originally pioneered for blood cancers through technologies like chimeric antigen receptor (CAR) T-cell therapies, the field is rapidly expanding into solid tumours, autoimmune conditions, and neurological diseases. Australia has close ties to CAR T-cell therapy development. Melbourne-based Cell Therapies Pty Ltd, the country's largest Therapeutic Goods Administration (TGA) licensed cell and gene therapy manufacturer, was the commercial production partner for Novartis's Kymriah – the first CAR T-cell therapy approved by the US Food and Drug Administration (FDA) in 2017. While the science remains complex, advances in manufacturing, engineering, and clinical design are making next-generation cell therapies more accessible and scalable, positioning them as a key pillar of future healthcare. Several ASX biotechs are positioning themselves at the forefront of cell therapies to capture a share of the global market, which accounted for ~US$6.04 billion in 2024 and is anticipated to close in on US$48bn by 2034, growing at a CAGR of almost 23%. In particular focus here is the treatment of solid tumours, which account for 90% of all cancers but have so far proven difficult to treat with cell therapies. Arovella in rare biotech club targeting CAR-iNKT therapies Arovella Therapeutics (ASX:ALA) is the only ASX-listed biotech delving into CAR Invariant Natural Killer T-cells (iNKT) therapies, and one of only a few globally. CEO Dr Michael Baker told Stockhead iNKT cells were distinct from the more familiar natural killer, or NK cells, which along with T-cells had limitations. T-cells can't be used off-the-shelf unless they are genetically engineered. While NK cells can quickly eliminate abnormal cells such as tumour cells, iNKT cells go further. Not only do they kill like T and NK cells, but they also trigger a longer-lasting response by activating other key parts of the immune system. Because iNKT cells recognise foreign threats differently – unlike classic CAR-T cells – it has been shown in clinical trials that iNKT cells do not cause complications like graft-versus-host disease (GvHD) when administered from a healthy donor to a patient. The FDA has approved seven CAR-T therapies to date, all for blood cancers, but no iNKT treatments. While over 120 global trials are investigating CAR-NK therapies for blood and solid tumours, CAR iNKT research remains limited. Baker said most cell therapies use the patient's own cells (autologous), but this was costly, slow, and relies on compromised cells. Arovella is taking an allogeneic approach, using healthy donor cells to create off-the-shelf, frozen doses shipped to clinics as needed in a 'ready-to-use' model. Its lead therapeutic ALA-101 combines iNKT cells with a CAR that targets CD19, a protein commonly found on B-cell blood cancers like lymphoma and leukaemia. One of Arovella's next key milestones is to apply to the FDA for its first-in-human trial, enrolling non-Hodgkin's lymphoma and leukaemia patients. The company's other key goal is also tackling solid tumours. "The first approved blood cancer targeting CAR-T products have demonstrated just how important cell therapies will be for cancer treatment," Baker said. "We look forward to using our CAR-iNKT cell platform to expand upon that work and aim to create products capable of increasing access and reducing costs. "There is a lot of great science that will continue to advance the off-the-shelf cell therapy sector. "That is why we continue to scour the globe for new IP to build into our CAR-iNKT platform, to either strengthen our CAR-iNKT cells or to broaden the cancer types that we can target.' Imugene also aims to crack solid tumours Imugene (ASX:IMU) is developing cell-based immunotherapies, including allogeneic CAR T-cell therapies, oncolytic viruses and B-cell vaccines, to address both blood cancers and solid tumours. The company's lead cell therapy candidate azercabtagene zapreleucel (azer-cel) is an off-the-shelf CAR T-cell therapy targeting CD19, a protein commonly expressed on malignant B-cells. There are no allogeneic (off the shelf) CAR T therapies approved to date. Azer-cel is currently undergoing clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a hard-to-treat form of non-Hodgkin's lymphoma. In early-phase studies, azer-cel has demonstrated promising results, including high complete response rates and durable remissions in patients who have previously relapsed after autologous CAR T-cell therapies. "We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T," CEO and managing director Leslie Chong told Stockhead. Imugene's next-generation cell therapy platform OnCARlytics is designed to help overcome one of the biggest challenges in cancer treatment, making solid tumours visible to the immune system. The approach combines Imugene's proprietary CF33 oncolytic virus, which selectively infects and destroys cancer cells, with CD19-targeting CAR T-cells. The CF33 infects tumour cells and forces them to express CD19, a marker typically found on blood cancer cells but absent on solid tumours. By introducing CD19 into the tumour environment, the therapy effectively tags the cancer, allowing CD19-specific CAR T-cells to recognise and attack the tumour. Imugene's pipeline also includes multiple immunotherapy B-cell vaccine candidates, which involve inducing the body to produce polyclonal antibodies against specific tumour-associated antigens. The company's PD1-Vaxx is designed to generate antibodies that block the PD-1 receptor, potentially mimicking the effects of checkpoint inhibitors such as pembrolizumab (Keytruda). The company recently announced the first patient had been dosed in Australia as part of an investigator-sponsored Phase II Neo-POLEM clinical trial, which is evaluating PD1-Vaxx's potential to improve treatment outcomes for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-high) colorectal cancer. This aggressive cancer subtype accounts for ~15% of all colorectal cancer cases. Chimeric advances cell therapy assets in solid tumours Chimeric Therapeutics (ASX:CHM) has three CAR T and NK cell assets in clinical trials. It has an ongoing phase 1/2 clinical trial for its novel CHM CDH17 CAR T-cell therapy targeting advanced colorectal cancer and Neuroendocrine tumours of the midgut. Their second program CHM CLTX CAR T is in a phase 1B clinical trial in recurrent/progressive glioblastoma, a form of brain cancer. CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial, demonstrated safety and efficacy in blood cancers and solid tumours. Two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated in Acute Myeloid Leukemia (AML). "We're excited to be actively advancing in the clinic and pushing through dose levels as we break new ground in the solid tumour CAR T-cell therapy space," CEO Dr Rebecca McQualter told Stockhead. Prescient advancing cell therapy platforms While predominately focused on PTX-100, its first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), Prescient Therapeutics (ASX:PTX) is also advancing its proprietary OmniCAR and CellPryme platforms. OmniCar has potential to allow CAR T therapy cells to be more targeted, safer, more effective, cost-effective and of longer duration. CellPryme is a complementary application to OmniCar split into two components. CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. Meanwhile, CellPryme-A acts as an adjuvant therapy, increasing the expansion of CAR T-cells and enhancing their ability to penetrate the tumour. AdAlta adopts East to West cellular immunotherapy strategy AdAlta (ASX:1AD) and venture capital firm SYNthesis BioVentures Fund (SYNBV) launched AdCella in 2024 to adopt an East to West strategy and bring cutting-edge cellular immunotherapies from Asia, particularly China, into Western markets. SYNBV was co-founded by Professor Andrew Wilks, who alongside Amplia (ASX:ATX) CEO Dr Chris Burns received the 2024 Prime Minister's Prize for Innovation for co-inventing momelotinib, an FDA-approved treatment for myelofibrosis. The strategy leverages AdAlta managing director and CEO Dr Tim Oldham's deep expertise in cellular immunotherapies and extensive operational experience in Asia to identify and advance promising Asian cellular therapies that can be transitioned into regulated western markets. Oldham was previously CEO of Cell Therapies and said he'd been fortunate to witness firsthand the rapid evolution of China's biotech sector and remarkable progress in cellular immunotherapies for cancer treatment over the past 15 years. The East to West cellular immunotherapy strategy for cancer is now a core growth priority for AdAlta and a key driver of future pipeline growth and value creation.

News.com.au
6 hours ago
- News.com.au
Research highlights huge gaps in screenings for different types of cancer
More than 230,000 deaths have been prevented by Australian cancer control measures during the past six decades, new research shows. A study published in the Australian and New Zealand Journal of Public Health on Wednesday points to anti-smoking campaigns and breast cancer screenings in particular as saving thousands of lives. 'What we're seeing is a snowball effect – we're now seeing the result of investments made in cancer control over the many decades,' lead researcher Brigid Lynch said. Since the mid-60s, more than 230,000 lives have been saved by developments in cancer controls. Sixty-five per cent of the avoided deaths occurred in the final 10 years of the study period (2009 to 2018), showing progress in the fight against cancer has accelerated, the researchers say. The study finds the mortality rate for breast, cervical and stomach cancer has dropped considerably. However, the chance of dying from liver or brain cancer continues to rise. 'These are trends we've seen both in Australia as well as around the world,' Associate Professor Lynch said. 'While we know more women are diagnosed with breast cancer today because of increased screening, thanks to early detection and improved treatment options, that mortality rate is falling. 'Quit campaigns in the 1980s impacted smoking prevalence and led to a drop in lung cancer deaths.' The study involved Cancer Council Victoria, the University of Melbourne, Baker Heart and Diabetes Institute, and Monash University. Cancer Council Australia scientific adviser Bernard Stewart, who was not involved in the study, said the lives saved over the past decades were a result of prevention, early diagnosis and better treatments. But the research showed nothing more precise for cancer generally, as various cancers 'must be considered separately to reveal specific achievements or lack thereof'. 'Frustratingly, specific progress for one type of cancer is rarely applicable to all tumour types, illustrating what an insidious disease cancer is,' Professor Stewart said. 'Concerning prevention, we know the cause of virtually all cervical and lung cancer cases, some bowel and breast cancer cases, while brain and prostate cancer can't be described this way. 'Early diagnosis comes from screening for cervical (to be displaced by vaccination), breast, bowel and lung cancer, but prostate cancer remains challenging and no screening yet for liver, stomach or ovarian cancer. 'Markedly improved survivability is evident for breast, bowel and other cancers but not for lung, pancreatic and brain cancer.' For this latest study, the researchers took World Health Organisation global health data, and analysed it against age-standardised cancer mortality rates from 1950 to 2018, finding more than 230,000 deaths have been avoided. Professor Lynch hopes the findings help health authorities prioritise cancer funding and campaigns. 'It's vital that society increases investment in cancer prevention and early detection efforts to help save lives,' she said. 'We are anticipating a significant increase of cancer incidence over the coming years due to our ageing and growing population. 'Prevention is the only way we can reduce the health, social and economic burden of cancer and protect our healthcare system.'

ABC News
12 hours ago
- ABC News
Australia scientists closer to Hendra virus vaccine thanks to nanobodies from Chilean alpaca names Pedro
An unlikely hero has emerged in the fight against the "absolutely terrifying" Hendra virus, which has again reared its head in Southeast Queensland, killing a horse for the first time in three years. Hendra — named after the Brisbane suburb that saw its first outbreak in 1994 — is highly lethal to horses and humans. The hero, 12,000 kilometres away, is Pedro, an eight-year-old Chilean alpaca living in South America. "His story is quite unique," said Dr Ariel Isaacs, an infectious diseases virologist at the University of Queensland, who used the alpaca in his latest Hendra research breakthrough. "Pedro was gifted by a travelling Tibetan Buddhist master to the Universidad Austral de Chile when he came to visit their facility a few years ago," he said. Dr Isaacs' and Pedro's worlds collided as a matter of scientific serendipity. The researcher first collaborated with the Chilean university during the pandemic, while working on a therapy for COVID-19. "Nanobodies are very specialised antibodies that can neutralise some viruses with very high potency," Dr Isaacs said. Camelids, including alpacas and llamas, are some of the only species worldwide that have nanobodies. "If you introduce a part of the virus into an alpaca, it will produce an immune response — and then it well develop nanobodies against that target. And the Chileans had isolated a nanobody that worked against COVID," he said. The outcome exceeded expectations. "We were optimistic that this would work but it was even better than we can have predicted," Professor Daniel Watterson, Dr Isaacs' colleague at the University of Queensland, told 7.30. Professor Watterson oversees a team including Dr Isaacs which makes vaccines and therapies for emerging deadly viruses with pandemic potential. Professor Watterson said that once Pedro started making nanobodies "we isolated a particular one that had a really high affinity and ability to protect against the virus in-vitro". "Then we're able to test that in animal models and prove that protects against infection." Dr Isaacs described it as a "eureka moment", and the Chilean collaborators named the nanobody 'DS90', with the finer details published in the revered Nature Structural and Molecular Biology journal. Dr Isaacs said with it, they now have the foundation to produce a powerful therapy. "What we want to do is turn it into a therapeutic treatment that we could eventually give to a human who might be infected by these viruses," he said. "And so I'm optimistic and I'm hopeful that funding comes through and we're able to take this into the clinic. "That would be really amazing for me as an individual, and amazing for the community, and for the lab and our collaborators, and for anybody who's affected by these diseases." The University of Queenland's infectious disease experts are concerned the Henipaviruses will mutate and spillover. "Nipah virus, for example, is something that is now emerging across Asia, India and Bangladesh in particular," Professor Watterson told 7.30. There have been cases of possible human-to-human transmissions and "that's where you're seeing potential for really explosive outbreaks", he warned. There have been 68 Hendra outbreaks resulting in 110 horse deaths since its discovery in 1994, including one in Southeast Queensland last week — the case of a horse that wasn't vaccinated. The virus is carried by flying foxes and shed in their excrement, and commonly contracted by horses in contaminated pastures, feed or water. "It is currently estimated that 70 to 80 per cent of bats are seropositive for Hendra virus, and that means that sometime in their lifetime they've carried the virus," Dr Isaacs told 7.30. "That's the point of concern for us, because it means that it's still circulating within bat populations, and then that means it can still transmit to horses and the horses can transmit to people — and that can cause severe disease. Dr Peter Reid was the first veterinarian to treat horses carrying Hendra, before anyone knew what it was, back in September 1994. He described it as an "absolutely catastrophic, horrifying experience". "It's always traumatic coming out and doing an interview again," Dr Reid told 7.30. "But I can understand the interest, and if it has the benefit of reminding people how horrendous it was and the ways to stop it happening, that's what I'm all for." Dr Reid had been called to Williams Avenue in Hendra to attend Victory Lodge, the Brisbane stables of his client and friend, racehorse trainer Vic Rail. Several of Mr Rail's horses had fallen ill and they couldn't figure out why. "There were a lot of sick horses and a lot of dying horses I had to put out of their misery by injecting them, and some of them I couldn't inject because they were thrashing around so badly," Dr Reid recalled. "In the space of 36 hours, I think there were nine horses that died or I had to put down ... it was just catastrophic because I didn't know what was killing them. "Hendra virus attacks all organs in the body and particularly has focus on the lungs and the brain — so the horses are actually dying because they can't breathe because their lungs are filling up full of fluid. "We thought it could have been a poison or a toxin — certainly there's been no virus that had ever been known to medical or veterinary science that could do this." While detectives, health authorities, and scientists scrambled to figure out what had caused the animals' deaths, Mr Rail himself was struck down, showing symptoms similar to the horses. He's one of four people to have died from the disease since it was discovered — the human mortality rate stands at almost 60 per cent. "We know the best way to prevent people being infected to stop the transmission from fruit bats and horses to people, and that is by vaccinating the horses. "It's safe and effective, it breaks the cycle of transmission. "Don't think that it can't happen to you, because it can." Watch 7.30, Mondays to Thursdays 7:30pm on ABC iview and ABC TV Do you know more about this story? Get in touch with 7.30 here.